Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of CKD-389 (Dapagliflozin + Sitagliptin) in Healthy Volunteers
NCT04322032Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin and sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under Curve last at 48 hours and Maximum Plasma Concentration at 48 hours. Status: unknown.
02
Drugs
dapagliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04322032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322032.